NewsBenzingaRapport Therapeutics Commences Separate Underwritten Public Offerings Of $200M Of Shares And $150M Aggregate Principal Amount Of Convertible Senior Notes Due 2032 Rapport Therapeutics Commences Separate Underwritten Public Offerings Of $200M Of Shares And $150M Aggregate Principal Amount Of Convertible Senior Notes Due 2032 Benzinga 2026.10.27 20:35 (GMT+0) Open on Benzinga Other news EXCLUSIVE: Ryan Detrick Isn’t Worried About Midterm Election Outcome – ‘Focus on the Fundamentals’ DA Davidson Maintains Neutral on RideNow Group, Lowers Price Target to $5 Nvidia China Trouble Could Spill Over to These AI Chip Stocks Wall Street Looks Beyond US Stocks: Morgan Stanley’s Europe Call Puts These ETFs on the Radar Fed's Hammack Says Businesses Are Passing On More Price Increases; Says Job Market Has Been Largely In Balance, But Is Not Dynamic Citigroup Maintains Buy on Nebius Group, Lowers Price Target to $215
Fed's Hammack Says Businesses Are Passing On More Price Increases; Says Job Market Has Been Largely In Balance, But Is Not Dynamic